Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
November 16, 2022 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the 2022 Deloitte Technology Fast 500™, a list of the fastest-growing...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
November 06, 2022 10:35 ET
|
Vir Biotechnology, Inc.
– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – –...
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:03 ET
|
Vir Biotechnology, Inc.
- Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 28, 2022 18:06 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 11, 2022 16:03 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
September 22, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...